Characterization of a membrane-active anti-tumor agent, UA8967

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Deletions or mutations in the DPC4 tumor suppressor gene are prevalent in pancreatic and colon cancers.
• Identifying novel therapeutic agents targeting DPC4-deficient tumors is crucial.

Purpose of the Study:

• To evaluate the efficacy and mechanism of action of a novel agent, UA8967, against DPC4-deleted cancer cells.
• To investigate UA8967's effects on cell viability, cell cycle, and plasma membrane integrity.

Main Methods:

• Target-related Affinity Profiling (TRAP) screening identified UA8967.
• Cytotoxicity assays were performed on multiple pancreatic and colon cancer cell lines, including DPC4-deleted and wild-type HCT-116 cells.
• Cell cycle analysis, apoptosis assays, and plasma membrane integrity tests (Sytox® Green, trypan blue, LDH leakage) were conducted.

Main Results:

• UA8967 exhibited potent cytotoxicity (IC50s 12-61 μM) in DPC4-deleted cancer cells.
• The drug induced G0/G1 cell cycle arrest and triggered an autophagic response followed by caspase-independent apoptosis and necrosis.
• UA8967 demonstrated a dose-dependent disruption of plasma membrane integrity, with DPC4(-/-) cells showing increased sensitivity.

Conclusions:

• UA8967 is a promising novel agent with significant cytotoxic effects on DPC4-deleted colon and pancreatic cancer cells.
• The compound's mechanism involves disruption of plasma membrane integrity, suggesting a targeted therapeutic approach.